HMGB1 and cancer: Here, by studying the immune-based effects of BLM anti-cancer treatment, we show that BLM is capable to cause ER and oxidative stress, CRT exposure, HMGB1 release, autophagy and ATP release, providing all the elements required to induce an ICD, leading to IFNγ and CD8+ T cell response against tumor cells.